Results 201 to 210 of about 78,173 (258)

Comparative Effectiveness of Upadacitinib vs. Other JAK Inhibitors in Patients With Rheumatoid Arthritis in a Global Real-World Setting. [PDF]

Rheumatol Ther
Taylor PC, Kadakia A, Milligan J, Romero A, Howell O, Patel PA, Barlow S, Caporali R.   +7 more
europepmc   +1 more source

Arginine methylation as a regulatory ratchet in cancer: From substrate selection to malignant‐state stabilization

Molecular Oncology, EarlyView.
Arginine methylation can be viewed as a persistence‐prone post‐translational modification regulated by a network of PRMTs. Competitive and compensatory interactions among PRMTs can redistribute methylation across substrate pools shaped by sequence, structural, spatial, and environmental layers, reinforcing RNA‐processing, chromatin, and signaling ...
So Hyun Kwon, Ji Min Lee
wiley   +1 more source

Strategies for Managing Suboptimal Response to JAK Inhibitors in Alopecia Areata. [PDF]

Acta Derm Venereol
Seyed Jafari SM, De Viragh PA.
europepmc   +1 more source

Use of JAK Inhibitors in Lichen Planus: An Update. [PDF]

Medicina (Kaunas)
Didona D, Caposiena Caro RD, Calabrese L, D'Onghia M, Galluccio G, Di Nicola MR, Rallo A, Paolino G.   +7 more
europepmc   +1 more source

JAK inhibitors alleviate EGFR-inhibitor-induced diarrhea by protecting intestinal stem cells from adaptive-immune-exacerbated injury. [PDF]

Nat Commun
Cheng Y, Xu C, Lv D, Tian M, Wang H, Yang B, Chen L, You Q, Zhang S.   +8 more
europepmc   +1 more source

JAK Inhibitors and Risk of Cancer in IBD Patients. [PDF]

Cancers (Basel)
Bernardi F, Faggiani I, Parigi TL, Zilli A, Allocca M, Furfaro F, Peyrin-Biroulet L, Danese S, D'Amico F.   +8 more
europepmc   +1 more source

JAK Inhibitors for Treatment of SAPHO Syndrome: A Systematic Review of 72 Cases. [PDF]

ACR Open Rheumatol
Fazeli P, Bahramian S, Farahmand K, Ghoshouni H, Farahmand Y, Soheili A, Bagheri L, Memari H, Feyzi A, Vahabi SM.   +9 more
europepmc   +1 more source

Topical Ruxolitinib and Delgocitinib Versus Systemic JAK Inhibitors: A Comparative Safety Review. [PDF]

Int J Mol Sci
Böll SL, Seyed Jafari SM, Conrad C, Schlapbach C.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

An Update on JAK Inhibitors

Current Medicinal Chemistry, 2019
Janus kinases (JAKs) are a family of non-receptor tyrosine kinases, composed by four members, JAK1, JAK2, JAK3 and TYK2. JAKs are involved in different inflammatory and autoimmune diseases, as well as in malignancies, through the activation of the JAK/STAT signalling pathway.
Giancarlo Grossi, Chiara Brullo, Silvia Schenone   +2 more
exaly   +4 more sources

Selective JAK Inhibitors

Future Medicinal Chemistry, 2014
Consisting of four members, JAK1, JAK2, JAK3 and TYK2, the JAK kinases have emerged as important targets for proliferative and immune-inflammatory disorders. Recent progress in the discovery of selective inhibitors has been significant, with selective compounds now reported for each isoform.
Brian W, Dymock, Eugene Guorong, Yang, Yuyi, Chu-Farseeva, Lianbin, Yao   +3 more
openaire   +2 more sources